Is Check Point (CHKP) Using Its New AI Governance Service To Redefine Its Cyber Moat?

• On 5 March 2026, Check Point Software Technologies launched its Secure AI Advisory Service, offering tiered governance, risk management and regulatory readiness support across the entire AI lifecycle, aligned with frameworks such as the EU AI Act, GDPR, ISO 42001 and NIST AI RMF.
• This new service, embedded within the CPR Act unit and powered by global threat intelligence, positions Check Point as a single, vendor-agnostic partner for operational AI risk management across hybrid and multivendor environments.
• We’ll now examine how this Secure AI Advisory launch, particularly its focus on embedded AI governance and compliance, influences Check Point’s investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Check Point Software Technologies Investment Narrative Recap

To own Check Point, you need to believe its prevention focused security stack and Infinity platform can keep winning enterprise budgets despite slower forecast growth, rising competition in SASE and AI, and macro related deal slippage. The Secure AI Advisory launch strengthens the near term catalyst around AI centric security and governance, but is unlikely to materially shift the biggest near term risk, which remains competitive intensity and execution across newer offerings.

The most relevant recent announcement alongside Secure AI Advisory is Check Point Exposure Management, introduced in January 2026. Together, these offerings aim to deepen Check Point’s role in exposure reduction and AI risk oversight across multivendor environments, which ties directly into the company’s focus on cross platform adoption as a key revenue driver and helps support the Infinity led catalyst around broader customer spend consolidation.

Yet while AI governance could support new service revenue, investors should still be aware of the competitive and margin pressure risk that comes with...

Read the full narrative on Check Point Software Technologies (it's free!)

Check Point Software Technologies' narrative projects $3.1 billion revenue and $989.0 million earnings by 2028. This requires 5.9% yearly revenue growth and a roughly $130.9 million earnings increase from $858.1 million today.

Uncover how Check Point Software Technologies' forecasts yield a $204.61 fair value, a 31% upside to its current price.

Exploring Other Perspectives

Five fair value estimates from the Simply Wall St Community range from US$108.10 to US$204.61, highlighting how far apart individual views can be. Set that against the current focus on AI led security catalysts and the ongoing risk of intensified SASE and AI competition, and it becomes clear you should compare several perspectives before deciding where Check Point fits in your portfolio.

Explore 5 other fair value estimates on Check Point Software Technologies - why the stock might be worth as much as 31% more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Check Point Software Technologies research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Check Point Software Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Check Point Software Technologies' overall financial health at a glance.

Searching For A Fresh Perspective?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Uncover the next big thing with 32 elite penny stocks that balance risk and reward.
• Outshine the giants: these 19 early-stage AI stocks could fund your retirement.
• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com